Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Plan B FOIA lawsuit

This article was originally published in The Tan Sheet

Executive Summary

Public interest group Judicial Watch has filed a lawsuit against FDA regarding a Freedom of Information Act request on Barr's Plan B, the group announces March 27. The suit, filed March 21 in the U.S. District Court for the District of Columbia, seeks an order to compel FDA to comply with Judicial Watch's Aug. 22 FOIA request seeking communications between FDA and Sen. Hillary Clinton, D-N.Y., regarding Plan B. FDA approved the drug for OTC use for women 18 and older in August 2006 (1"The Tan Sheet" Aug. 28, 2006, p. 3). "This was a simple request for documents and the FDA's delay in producing them is curious," Judicial Watch says...

You may also be interested in...



Plan B Pioneers OTC “Pharmacy Counter” Approval, Dual-Status Marketing

FDA's decision to approve emergency contraceptive Plan B for over-the-counter sale to women age 18 and older cracks open the door on a pharmacy-only, behind-the-counter model for nonprescription drug sales

Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA

AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.

World-First Nod For Yuhan's Lung Cancer Drug, In Korea

The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.

Topics

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel